Innoviva (INVA) Misses Q3 EPS by 25c

Innoviva (NASDAQ: INVA) reported Q3 EPS of $0.02, $0.25 worse than the analyst estimate of $0.27. Revenue for the quarter came in at $89.51 million versus the consensus estimate of $76.91 million.

For earnings history and earnings-related data on Innoviva (INVA) click here.

You May Also Be Interested In

• Paychex (PAYX) Tops Q1 EPS by 2c
• Glucotrack unit submits LT-100 clinical protocol for osteoarthritis
• BMO Capital on National Health Investors (NHI): 'Acquisitions Accelerating; SHOP Growth Execution Key'